Clinical Trial Update: Investigation of the Pharmacokinetic Profile of CBD [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the pharmacokinetic profile of cannabidiol (CBD) in participants with opioid use disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Yasmin Hurd | Conditions: Opioid Use Disorder | Phase 1 | Status: COMPLETED